Trial Profile
Phase 2 study of afatinib in patients with previously treated advanced non-sq NSCLC haboring EGFR mutation
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 29 Aug 2014
Price :
$35
*
At a glance
- Drugs Afatinib (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 29 Aug 2014 New trial record